Dermatologic Disease clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

    open to eligible people ages 18-75

    This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.

    Los Angeles, California and other locations

Our lead scientists for Dermatologic Disease research studies include .

Last updated: